All In Biotech

Drug Trial Radar · NCT04667078

REperfusion With P2Y12 Inhibitors in Addition to mEchanical thRombectomy for perFUsion Imaging Selected Acute Stroke patiEnts

REperfusion With P2Y12 Inhibitors in Addition to mEchanical thRombectomy for perFUsion Imaging Selected Acute Stroke patiEnts (REPERFUSE)

Last checked: Nov 20, 2026Latest source record: Sep 25, 2026 (this record)Source: ClinicalTrials.govMethods & limitations

SuspendedPivotal-lookingPhase 3. Randomized with 368 participants. This is a heuristic, not a regulatory label.

Status

Suspended

Enrollment

368

Planned (sponsor's estimate)

Start

Mar 2, 2022

Primary completion

Dec 21, 2026

Study completion Dec 21, 2027

Sponsor

Sponsor type
Research network
Collaborators
Ministry of Health, France
First posted
Dec 14, 2020

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 3
Allocation
Randomized
Model
Parallel
Masking
Single (participant)
Primary purpose
Treatment
FDA-regulated drug
No
Who can join
All sexes, from 18 years, up to 80 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

The main objective is to evaluate the efficacy of IV administration of the P2Y12 inhibitor (cangrelor) in addition to mecanich thrombectomy and WMD versus mecanich thrombectomy and WMD alone on the functional prognosis at 3 months, in patients with acute ischemic stroke eligible for mecanich thrombectomy on the basis of infusion imaging between 0 and 24 hours after the onset of symptoms.

Conditions

  • Acute Ischemia

Interventions

  • CangrelorDrug

    administration of cangrolor by iv befor thrombectomy

  • best medical managementOther

    used yhe best medical management

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Favorable functional evaluation at 3 month for patients with acute ischemic strocke treated by cangrelor.Time frame: 3 months

Locations

13 sites in 1 country. Site status is shown where the registry gives one.

  • CHU de Besançon

    Besançon, France

  • Hôpital Pellegrin (CHU de Bordeaux)

    Bordeaux, France

  • Hospices civils de Lyon, Hôpital Pierre Wertheimer

    Bron, France

  • Hôpital Salengro (CHU Lille)

    Lille, France

  • Hôpital Dupuytren (CHU Limoges)

    Limoges, France

  • CHU La Timone

    Marseille, France

  • Hôpital Central (CHU de Nancy)

    Nancy, France

  • Hôpital Lariboisière AP-HP

    Paris, France

  • Hôpital Pitié-Salpêtrière AP-HP

    Paris, France

  • Hôpital Fondation A de Rothschild

    Paris, France

  • CHU de Strasbourg

    Strasbourg, France

  • Hôpital Foch

    Suresnes, France

  • Hôpital Purpan (CHU de Toulouse)

    Toulouse, France

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.